GlaxoSmithKline starts late-stage trial for experimental antibiotic

Credit: REUTERS/STAFF

GlaxoSmithKline Plc said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.

Adds study details

Oct 28 (Reuters) - GlaxoSmithKline Plc GSK.L said on Monday it has begun a late-stage study testing its experimental antibiotic in patients with urinary tract infections and gonorrhoea, a type of sexually transmitted infection.

The antibiotic, gepotidacin, is the first of a new class of drugs and is expected to treat two common bacterial infections, which have been identified as antibiotic resistant threats by U.S. health regulators.

Health officials across the world have called for the development of newer versions of antibiotics as the growing problem of antibiotic resistance renders some of the most commonly prescribed treatments ineffective.

GSK's antibiotic will be compared to a combination of ceftriaxone and azithromycin in about 600 patients with urogential gonorrhoea, and against nitrofurantoin in nearly 1,200 women with urinary tract infections. (https://bit.ly/32RNPKN)

Gepotidacin works by selectively interacting with two bacterial enzymes that aid in bacterial replication, making its mechanism of action different from other approved antibiotics, the company said.

GSK expects to announce initial results from the study by the end of 2021.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)

((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 2290; Twitter: @SaumyaSibi))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More